1. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547–53.
2. Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009;25:2989–99.
3. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761–71.
4. Bapurso G, Bettini R, Rinzivillo M, et al. Role of resection of the primary pancreatic neuroendocrine tumor only in patients with unresectable metastatic liver disease: a systematic review: Neuroendocrinology 2011;93:223–9.
5. Bettini R, Mantovani W, Boninsegna L, et al. Primary tumor resection in metastatic non-functioning pancreatic endocrine carcinomas. Dig Liver Dis 2009;41:49–55.
6. Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in non-functioning pancreatic endocrine tumors. Surgery 2011;150:75–82.
7. Bousquet C, et al. Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 2012;97:727–37.
8. Burgus R, Ling N, Butcher M, Guillemin R. Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proc Natl Acad Sci 1973;70:684–8.
9. Bushnell DL Jr., O’Dorisio TM, Menda Y, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652–9.
10. Caplin M, Ruszniewski P, Pavel M, et al. EJC 2013;47(Suppl 2):Abstract.
11. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012;30:2963–8.
12. Chiu CW, Nozawa H, Hanahan D. Survival benefit with pro-apoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010;28:4425–33.
13. Chow LQ, Eckhardt S. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884–96.
14. Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 2010;21:787–94.
15. Debono M, Hon LQ, Bax N, et al. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs. J Clin Endocrinol Metab 2008;93:1860–4.
16. European Neuroendocrine Tumor Society. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors. Neuroendocrinology 2012;95:67–177.
17. Faiss S, Pape UF, Böhmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the international lanreotide and interferon alfa study group. J Clin Oncol 2003;21:2689–96.
18. Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381–7.
19. Hellman P, Lundström T, Ohrvall T, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002;36:991–7.
20. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416–23.
21. Jann H, Denecke T, Koch M, et al. Impact of octreotide long-acting release on tumor growth control as a first-line treatment in neuroendocrine tumors of pancreatic origin. Neuroendocrinology 2013;98: 137–43.
22. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22: 4762–71.
23. Kulaksiz H, Eissele R, Rössler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumors with subtype specific antibodies. Gut 2002;50:52–60.
24. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.
25. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246–54.
26. Mitry E, Walter T, Baudin E, Kurtz J-E, et al. Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study). J Clin Oncol 2012 (suppl; abstr 4071).
27. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 2010;31:169–88.
28. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227–32.
29. Moertel CG, Lefkopoulo M, Lipsitz S, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–23.
30. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2014. Neuroendocrine Tumors.
31. Northern American Neuroendocrine Tumor Society. The NANETS Consensus Guidelines for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas 2010;39:705–948.
32. Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994;55(Suppl 3):98–103.
33. Öberg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7): vii 124–30.
34. Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol 1907;1:426–29.
35. Pape UF, Jann H, Müller-Norhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256–65.
36. Pavel M, Baum U, Hahn EG, et al. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006;26:8–13.
37. Pavel M, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase 3 study. Lancet 2011;378:2005–12.
38. Pavel M. Translation of molecular pathways into clinical trials of neuroendocrine tumors. Neuroendocrinology 2013;97:99–112.
39. Plöckinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract & Res Clin Endocrinol Metab 2007;21:145–62.
40. Poitras P, Gingras M-H, Rehfeld JF. Secretin stimulation test for gastrin release in Zollinger-Ellison syndrome. Pancreas 2013;46:903–4.
41. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors (NETs). Gut 2012;61:6–92.
42. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139–43.
43. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13.
44. Raymond E, Niccoli P, Raoul J, et al. Updated overall survival and progression-free survival by blinded independent central review of sunitinib versus placebo for patients with advanced unresectable pancreatic neuroendocrine tumors. J Clin Oncol 2011;29(Suppl): abstr 4008.
45. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Hruban RH, Theise ND (eds). WHO Classification of Tumors of the Digestive System. Lyon: IARC, 2010:13–4.
46. Rindi G, Klöppel G, Ahlman H, Caplin M, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395–401.
47. Rindi G, Klöppel G, Couvelard A, Komminoth P, et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757–62.
48. Rinke A, Müller HH, Schade-Brittinger C, Klose JJ, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656–63.
49. Rothmund M, Kisker O. Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994;55(Suppl 3):86–91.
50. Sandostatin LARR Depot (octreotide acetate for injectable suspension). East Hanover, NJ: Novartis Pharmaceutical Corporation, 2010.
51. Signifor 0.3 mg solution for injection. West Sussex, UK: Novartis Europharm Limited, 2012.
52. Somatuline Autogel (summary of product characteristics). Uppsala, Sweden: Pharmacia, 2002.
53. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152–60.
54. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268–75.
55. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733–42.
56. Unger N, et al. Differential expression of somatostatin receptor subtype 1–5 proteins in numerous human normal tissues. Exp Clin Endocrinol Diabetes 2012;120:482–9.
57. Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of tomozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617–22.
58. Wild D, Bomanij JB, Benkert P, Maecke H, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013;54:364–72.
59. Yao JC, Hassan M, Phan A, Dagohoy C, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26: 3063–72.
60. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28: 69–76.
61. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316–23.
62. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
63. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109:1478–86.
Prof. Dr. med. Rudolf Arnold, Dr. med. Anja Rinke, Klinik für Gastroenterologie und Endokrinologie, Anneliese-Pohl-Krebszentrum Marburg, Comprehensive Cancer Center, Universitätsklinikum Gießen und Marburg, Standort Marburg, Baldingerstraße, 35043 Marburg, E-Mail: email@example.com